title: Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm.
abstract: BACKGROUND
  Retroperitoneal sarcoma (RPS) American Joint Committee on Cancer (AJCC) staging applies to primary tumors only; due to specific RPS disease characteristics, staging is driven primarily by grade, stratifying patients into only two distinct prognostic subsets. The objective of this study was to help improve currently available staging for RPS by establishing a new, more robust histology-based prognostic system.
  
  
  METHODS
  A RPS database of 1,118 patients seen at our institution (1996-2006) identified 343 patients treated for resectable primary or recurrent disease; a histologic subtype-based RPS prognostic system was designed and evaluated for prognostic accuracy in comparison with the current AJCC staging system.
  
  
  RESULTS
  Histology stratified patients into three groups by prognosis (P<0.0002): atypical lipomatous tumor (ALT), non-ALT liposarcoma (LPS), and "other," an improvement compared with AJCC staging which could only identify two distinct prognostic groups. In contrast to AJCC staging, this prognostic stratification was reproducible for both primary and recurrent RPS (P<0.0001). After multivariate analysis, LPS (P=0.0004) and "other" histologies (P<0.0001) were found to be independent predictors of worse survival. The concordance ratio of this model was 0.74, equivalent to that of the model using the AJCC staging system.
  
  
  CONCLUSIONS
  A histology-based RPS prognostic system has two advantages over AJCC staging: it can stratify into three versus two distinct prognostic groups, and it can be used for both primary and recurrent RPS. Distinct risk stratification is critical for specific assessment of prognosis as well as decisions regarding individualized adjuvant therapies, hence the advantage of a three-tiered histology-based system applicable in both primary and recurrent RPS.
authors.affiliation: Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77030-4009, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Anaya
authors.forename: Guy
authors.initials: G
authors.lastname: Lahat
authors.forename: Xuemei
authors.initials: X
authors.lastname: Wang
authors.forename: Lianchun
authors.initials: L
authors.lastname: Xiao
authors.forename: Daniel
authors.initials: D
authors.lastname: Tuvin
authors.forename: Peter W
authors.initials: PW
authors.lastname: Pisters
authors.forename: Dina C
authors.initials: DC
authors.lastname: Lev
authors.forename: Raphael E
authors.initials: RE
authors.lastname: Pollock
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D011446:Prospective Studies; D012186:Retroperitoneal Neoplasms / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies; D018570:Risk Assessment; D012509:Sarcoma / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate; D013997:Time Factors; D055815:Young Adult